Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the target of a significant decline in short interest during the month of December. As of December 31st, there was short interest totalling 269,700 shares, a decline of 29.7% from the December 15th total of 383,700 shares. Currently, 6.8% of the company’s stock are short sold. Based on an average daily trading volume, of 1,050,000 shares, the short-interest ratio is currently 0.3 days.

Allarity Therapeutics Stock Up 4.0 %

NASDAQ ALLR opened at $1.03 on Friday. The firm’s fifty day moving average price is $1.13 and its two-hundred day moving average price is $2.87. Allarity Therapeutics has a 1 year low of $0.90 and a 1 year high of $299.40.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.